Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Pietro LocantoreRoberto NovizioAndrea CorselloRosa Maria ParagliolaAlfredo PontecorviSalvatore Maria CorselloPublished in: Expert opinion on drug discovery (2021)
Pralsetinib is a new generation oral treatment that has been approved by the FDA for patients with RET-mutated thyroid cancer. Pralsetinib showed a safer toxicity profile compared to previously approved MKI, probably due to lower inhibition of other tyrosine kinases, especially VEGFR. The approval study ARROW trial showed that patients with RET-mutant medullary thyroid cancer had a better overall response rate to pralsetinib compared to standard-of-care treatments. Additional clinical trials or data enrichment of existing databases are desirable in order to verify and further describe the clinical benefit of pralsetinib in such patients to fully understand its pharmacological profile.
Keyphrases
- clinical trial
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- drug administration
- small molecule
- chronic kidney disease
- peritoneal dialysis
- study protocol
- randomized controlled trial
- prognostic factors
- electronic health record
- stem cells
- machine learning
- phase ii
- cell therapy
- replacement therapy